Abstract
Cannabinoids, consiting of alkylresorcinol and monoterpene groups, are the unique secondary metabolites that are found only in Cannabis sativa. Tetrahydrocannabinol (THC), cannabidiol (CBD) and cannabichromene (CBC) are well known cannabinoids and their pharmacological properties have been extensively studied. Recently, biosynthetic pathways of these cannabinoids have been successfully established. Several biosynthetic enzymes including geranylpyrophosphate: olivetolate geranyltransferase, tetrahydrocannabinolic acid (THCA) synthase, cannabidiolic acid (CBDA) synthase and cannabichromenic acid (CBCA) synthase have been purified from young rapidly expanding leaves of C. sativa. In addition, molecular cloning, characterization and localization of THCA synthase have been recently reported. THCA and cannabigerolic acid (CBGA), its substrate, were shown to be apoptosis-inducing agents that might play a role in plant defense. Transgenic tobacco hairy roots expressing THCA synthase can produce THCA upon feeding of CBGA. These results open the way for biotechnological production of cannabinoids in the future.
Keywords: Cannabis sativa, cannabinoid, tetrahydrocannabinol, tetrahydrocannabinolic acid synthase, biosynthesis, glandular trichome and biotechnology
Current Pharmaceutical Biotechnology
Title: Recent Advances in Cannabis sativa Research: Biosynthetic Studies and Its Potential in Biotechnology
Volume: 8 Issue: 4
Author(s): Supaart Sirikantaramas, Futoshi Taura, Satoshi Morimoto and Yukihiro Shoyama
Affiliation:
Keywords: Cannabis sativa, cannabinoid, tetrahydrocannabinol, tetrahydrocannabinolic acid synthase, biosynthesis, glandular trichome and biotechnology
Abstract: Cannabinoids, consiting of alkylresorcinol and monoterpene groups, are the unique secondary metabolites that are found only in Cannabis sativa. Tetrahydrocannabinol (THC), cannabidiol (CBD) and cannabichromene (CBC) are well known cannabinoids and their pharmacological properties have been extensively studied. Recently, biosynthetic pathways of these cannabinoids have been successfully established. Several biosynthetic enzymes including geranylpyrophosphate: olivetolate geranyltransferase, tetrahydrocannabinolic acid (THCA) synthase, cannabidiolic acid (CBDA) synthase and cannabichromenic acid (CBCA) synthase have been purified from young rapidly expanding leaves of C. sativa. In addition, molecular cloning, characterization and localization of THCA synthase have been recently reported. THCA and cannabigerolic acid (CBGA), its substrate, were shown to be apoptosis-inducing agents that might play a role in plant defense. Transgenic tobacco hairy roots expressing THCA synthase can produce THCA upon feeding of CBGA. These results open the way for biotechnological production of cannabinoids in the future.
Export Options
About this article
Cite this article as:
Supaart Sirikantaramas , Futoshi Taura , Satoshi Morimoto and Yukihiro Shoyama , Recent Advances in Cannabis sativa Research: Biosynthetic Studies and Its Potential in Biotechnology, Current Pharmaceutical Biotechnology 2007; 8 (4) . https://dx.doi.org/10.2174/138920107781387456
DOI https://dx.doi.org/10.2174/138920107781387456 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Mutations in PRKN and SNCA Genes Important for the Progress of Parkinson’s Disease
Current Genomics Modulation of Monoaminergic Transporters by Choline-Containing Phospholipids in Rat Brain
CNS & Neurological Disorders - Drug Targets Current Concepts in Gastric Motility in Diabetes Mellitus
Current Diabetes Reviews Piribedil: Antiparkinsonian Properties and Potential Clinical Utility in Dopaminergic Disorders
Current Drug Therapy Curcumin: A Potential Neuroprotective Agent in Parkinson's Disease
Current Pharmaceutical Design L-Dopa Prodrugs: An Overview of Trends for Improving Parkinsons Disease Treatment
Current Pharmaceutical Design Applications of Nanotechnology in Diagnostics and Therapeutics of Alzheimer’s and Parkinson’s Disease
Current Drug Metabolism Adamantane – A Lead Structure for Drugs in Clinical Practice
Current Medicinal Chemistry Differences in Medication Adherence, Satisfaction and Clinical Symptoms in Schizophrenic outpatients Taking Different Antipsychotic Regimens
Current Drug Safety Recent Progress in Gene Therapy for Parkinson’s Disease
Current Molecular Medicine Brain-derived Neurotrophic Factor Genetic Variants are Associated with Major Depression Susceptibility and Serotonin Reuptake Inhibitor Antidepressant Treatment Response in Taiwanese
Current Pharmacogenomics and Personalized Medicine Cutting through the Complexities of mTOR for the Treatment of Stroke
Current Neurovascular Research Disorders of Consciousness and Electrophysiological Treatment Strategies: A Review of the Literature and New Perspectives
Current Pharmaceutical Design The Other Side of Opioid Receptor Signalling: Regulation by Protein-Protein Interaction
Current Drug Targets Phenytoin Induced Chorea: A Rare Adverse Effect of the Drug
Current Drug Safety Pharmacogenetic Studies of Psychotropic Drug-Induced Adverse Effects
Current Pharmacogenomics Simvastatin and Other HMG-CoA Reductase Inhibitors on Brain Cholesterol Levels in Alzheimers Disease
Current Alzheimer Research The Paradox of Caffeine-Zolpidem Interaction: A Network Analysis
Current Drug Targets Calpain as a Potential Therapeutic Target in Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Structure-Based Design, Synthesis and Molecular Modeling Studies of Thiazolyl Urea Derivatives as Novel Anti-Parkinsonian Agents
Medicinal Chemistry